1 |
peroxisome proliferator-activated receptor gamma
(328 times)
|
Endocrinology (37 times)
|
SNPs (24 times) T2DM (12 times) FASN (10 times)
|
1999 Lipid mediators that modulate the extracellular matrix structure and function in vascular cells.
|
2 |
PPARgamma
(12 times)
|
Endocrinology (3 times)
|
PPAR (6 times) OPG (2 times) PPARgamma (2 times)
|
2007 Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk.
|
3 |
proliferator-activated receptor-gamma
(6 times)
|
Molecular Biology (2 times)
|
MSCs (3 times) CEBPA (2 times) ADSCs (1 time)
|
2010 Analysis of two sequence variants in peroxisome proliferator activated receptor gamma gene in Tajik population at high altitudes and Han population at low altitudes in China.
|
4 |
PPARgamma gene
(5 times)
|
Metabolism (2 times)
|
PPARgamma (4 times) SNPs (2 times) BMI (1 time)
|
2002 Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene.
|
5 |
peroxisome proliferator receptor gamma
(1 time)
|
Physiology (1 time)
|
AFM (1 time) ASCs (1 time)
|
2015 Temporal heterogeneity in single-cell gene expression and mechanical properties during adipogenic differentiation.
|
6 |
PPARalpha and PPARgamma
(1 time)
|
Endocrinology (1 time)
|
GO (1 time) IFNG (1 time) TNF-alpha (1 time)
|
2012 beta (CCL2) and alpha (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-alpha agonists in Graves' ophthalmopathy.
|
7 |
PPARgamma coactivator
(1 time)
|
Medicine (1 time)
|
BMI (1 time) PPAR (1 time) qPCR (1 time)
|
2016 Body Mass Index in Pregnancy Does Not Affect Peroxisome Proliferator-activated Receptor Gamma Promoter Region (-359 to -260) Methylation in the Neonate.
|
8 |
proteins PPARgamma
(1 time)
|
Geriatrics (1 time)
|
BMD (1 time) hMSCs (1 time) hPBMCs (1 time)
|
2017 Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures.
|